📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-31 23:10
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
53 announcements match the current filters (relevance ≥ 5).
Neogen's subsidiary transfers LiPF6 business to step-down unit for ₹245 Cr
Neogen Chemicals announced an internal restructuring where its wholly owned subsidiary, Neogen Ionics Limited (NIL), will transfer its Electrolyte Salt (LiPF6) undertaking to step-down subsidiary Neogen Morita New Materials Limited (NML). The transaction is structured as a slump sale on a going concern basis for a net consideration of ₹245 Crore. The transferred undertaking contributed ₹0 in revenue for FY26 and has a net worth of ₹155.52 Crore (19.05% of consolidated net worth). The transaction is expected to be completed on or before March 31, 2027.
Confidence: HIGH
What changedNeogen approved the transfer of its LiPF6 undertaking from subsidiary NIL to step-down subsidiary NML for ₹245 Crore.
Why it mattersConsolidates electrolyte salt manufacturing under dedicated entity NML to streamline battery chemicals operations, with zero net impact on consolidated financials.
Transfer consideration: ₹245 CroreNet worth of undertaking: ₹155.52 CroreShare of consolidated net worth: 19.05%Completion target: March 31, 2027
📅 Short termNeutral immediate impact since this is an internal group restructuring between 100% owned subsidiaries without third-party cash outflow.
📈 Long termAligns strategic focus on the lithium-ion battery chemicals portfolio, facilitating focused scaling and potential partner integration for LiPF6 salts.
⚠ Risk flags
- Execution timeline for commissioning and commercializing the battery chemicals facilities by March 2027
Key Highlights
Internal business transfer of electrolyte salt assets to NML for ₹245 Crore consideration
Transferred undertaking has a net worth of ₹155.52 Crore (19.05% of consolidated net worth)
Target completion date for the BTA execution and transfer is on or before March 31, 2027
Consolidates Neogen's specialized Electrolyte Salt (LiPF6) operations under the Morita joint venture entity
👀 What to Watch
Track the execution of the BTA and commercialization timeline of the LiPF6 electrolyte salt manufacturing operations under NML towards FY27.
34% Revenue Growth in Q1 FY27; Neogen Raises Guidance and Plans ₹600 Cr QIP
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue growing 34% YoY to ₹250 cr and PAT surging 67% to ₹17 cr. Management has raised its standalone FY27 revenue guidance to ₹950–1,050 cr, reflecting confidence in the ramp-up of battery chemicals and organo-lithium segments. The Board approved a ₹600 cr QIP to deleverage the balance sheet and fund future growth, which represents approximately 11.2% of the current market capitalization. The Dahej replacement plant is nearing completion with commercial production expected to start in Q2 FY27.
Confidence: HIGH
What changedNeogen has shifted from a capacity-building phase to a revenue-generation phase, evidenced by a significant guidance upgrade and the successful ramp-up of its battery materials vertical.
Why it mattersThe company is positioning itself as a primary domestic supplier for the Indian EV battery ecosystem, which is projected to grow to 92 GWh by 2027. The ₹600 cr fundraise will significantly strengthen the balance sheet (current D/E 0.86) for this expansion.
Q1 FY27 Revenue: ₹250 crQ1 PAT Growth (YoY): 67%Proposed QIP Fundraise: ₹600 crQIP vs Market Cap: ~11.2%Revised FY27 Revenue Guidance: ₹950–1,050 crNet Insurance Claim Receivable: ₹186 cr
📅 Short termThe stock may see positive momentum following the guidance upgrade and strong Q1 earnings. The market will focus on the pricing of the ₹600 cr QIP and the resumption of the Dahej plant.
📈 Long termNeogen's strategic pivot toward battery chemicals and its partnership with Morita (Japan) for non-FEOC compliant supply chains could lead to structural re-rating as the domestic EV battery market scales toward 200 GWh by 2032.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the ₹600 cr QIP
- Execution risks in commissioning new battery chemical facilities
- Volatility in global lithium prices affecting raw material costs
Key Highlights
Consolidated revenue increased 34% YoY to ₹250 cr in Q1 FY27, driven by record organo-lithium and battery chemical sales.
EBITDA margins expanded by 260 basis points to 19.3%, resulting in a 53% YoY growth in EBITDA to ₹48 cr.
Board approved a fundraise of ₹600 cr via QIP to support long-term capital requirements and deleveraging.
Neogen Ionics (battery chemicals) generated ₹19 cr in Q1 FY27, already exceeding 50% of its entire FY26 revenue.
Standalone revenue guidance for FY27 revised upwards to a range of ₹950–1,050 cr from the previous ₹875–950 cr.
👀 What to Watch
Investors should monitor the commercial production commencement at the Dahej plant in Q2 FY27 and the progress of the ₹600 cr QIP. Key execution milestones to watch include the commissioning of the electrolyte plant in H1 FY27 and lithium electrolyte salts in H2 FY27.
Q1 FY27: 34% Revenue Growth; Board Approves Rs 600 Cr QIP for Battery Chemicals Expansion
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue growing 34% YoY to Rs 250.3 Cr and PAT surging 67% to Rs 17.1 Cr. The company is executing a massive Rs 1,795 Cr capex plan for battery materials, representing approximately 208% of its TTM revenue, with Rs 1,298 Cr already incurred. To fund this expansion and manage debt, the Board has approved a Rs 600 Cr QIP. While EBITDA margins improved to 19.3%, finance costs rose 64% YoY due to increased debt for ongoing projects.
Confidence: HIGH
What changedNeogen has transitioned from planning to heavy execution of its battery materials pivot, backed by a new Rs 600 Cr fundraise approval and the completion of the Dahej plant reconstruction.
Why it mattersThe massive capex (over 2x TTM revenue) into Lithium-ion battery materials could structurally re-rate the company if it successfully secures approvals from global cell manufacturers and manages its high interest burden.
Q1 FY27 Revenue (Consolidated): Rs 250.3 CrTotal Capex vs TTM Revenue: ~208%Proposed QIP Fundraise: Rs 600 CrFinance Cost Growth (YoY): 64%EBITDA Margin: 19.3%
📅 Short termThe stock may react positively to the 67% PAT growth and the clarity provided on the Dahej plant reconstruction and insurance recoveries.
📈 Long termThe company is betting heavily on the EV ecosystem; long-term value depends on the successful commissioning of the Rs 1,367 Cr Pakhajan facility by March 2027.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (up 64% YoY) impacting net margins
- Execution risk on the large-scale Rs 1,795 Cr capex
- Geopolitical freight spikes affecting input costs
Key Highlights
Consolidated PAT increased 67% YoY to Rs 17.1 Cr in Q1 FY27 from Rs 10.3 Cr in Q1 FY26
Total Battery Materials project cost estimated at Rs 1,795 Cr, with Rs 1,298 Cr (72%) already spent
Board approved raising up to Rs 600 Cr through a Qualified Institutional Placement (QIP)
Neogen Ionics revenue grew to Rs 19 Cr in Q1 FY27 compared to Rs 5 Cr in Q1 FY26
Dahej Phase 1 project (Rs 428 Cr) is on track for completion by February 2027
👀 What to Watch
Investors should track the execution timeline of the Pakhajan Phase 2 facility (March 2027) and the pricing/dilution impact of the upcoming Rs 600 Cr QIP.
34% Revenue Growth in Q1 FY27; Neogen Approves Rs 600 Cr QIP for Rs 1,795 Cr Battery Capex
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue rising 34% YoY to Rs 250.3 cr and PAT increasing 67% to Rs 17.1 cr. The battery chemicals subsidiary, Neogen Ionics, showed significant traction, contributing Rs 19 cr in revenue compared to Rs 5 cr in the previous year. The company is executing a massive Rs 1,795 cr capex plan for battery materials, which is approximately 208% of its TTM revenue. To support this, the board has approved a fundraise of up to Rs 600 cr via QIP, representing about 11% of its current market capitalization.
Confidence: HIGH
What changedNeogen has transitioned from recovering from the Dahej fire incident to an aggressive expansion phase in the EV battery materials sector, supported by a major new fundraise approval.
Why it mattersThe Rs 1,795 cr capex is transformative, representing over 2x the company's current annual revenue, pivoting the business toward high-growth Lithium-ion battery components.
Q1 FY27 Consolidated Revenue: Rs 250.3 crConsolidated PAT Growth (YoY): 67%Total Battery Capex Budget: Rs 1,795 crCapex vs TTM Revenue: 208.2%Proposed QIP Fundraise: Rs 600 crQIP vs Market Cap: 11.0%
📅 Short termThe stock may react positively to the strong margin expansion and the clarity provided on the Dahej plant restart and the funding roadmap for expansion.
📈 Long termThe structural shift into the EV battery supply chain (electrolytes and salts) could significantly re-rate the company if the 32,000 MT electrolyte capacity is successfully commissioned by FY27.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High interest costs (up 64% YoY) due to increased debt for capex
- Execution risk associated with the large-scale Pakhajan project
- Geopolitical supply chain inflation impacting working capital
Key Highlights
Consolidated EBITDA grew 53% YoY to Rs 48.2 cr, with margins expanding by 260 bps to 19.3%
Total estimated project cost for Battery Materials (Phase 1 & 2) stands at Rs 1,795 cr, with Rs 1,298 cr already incurred
Board approved a fundraise of up to Rs 600 cr through a Qualified Institutional Placement (QIP)
Neogen Ionics revenue reached Rs 19 cr in Q1 FY27, surpassing 50% of its entire FY26 revenue in one quarter
Cumulative insurance recoveries for the Dahej fire incident reached Rs 164 cr, with trial runs for the rebuilt plant now underway
👀 What to Watch
Watch for the successful pricing and completion of the Rs 600 cr QIP and the commercial production commencement at the rebuilt Dahej plant. Monitor the execution timeline of the Pakhajan Phase 2 project, which is critical for the FY27-28 growth targets.
67% PAT growth in Q1 FY27; Neogen approves ₹600 Cr QIP for ₹1,795 Cr battery project
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue rising 34% YoY to ₹250 crore and PAT increasing 67% YoY to ₹17 crore. Growth was driven by record revenues in Organolithium and a sharp ramp-up in the Battery Chemicals subsidiary (Neogen Ionics), which earned ₹19 crore vs ₹5 crore YoY. To fund its massive ₹1,795 crore battery materials expansion, the board approved a ₹600 crore QIP. While finance costs rose 64% due to debt-funded capex, the completion of the Dahej plant reconstruction and 72% capex deployment to date signal a major scale-up phase.
Confidence: HIGH
What changedNeogen has successfully transitioned its battery materials segment from development to revenue generation while securing board approval for a major equity fundraise to deleverage the balance sheet.
Why it mattersThe ₹1,795 crore capex is over 2x the company's TTM revenue, indicating a massive structural shift in scale. Successful execution could significantly re-rate the company as a key player in the global EV battery supply chain.
Q1 FY27 Revenue: ₹250 crQ1 FY27 PAT Growth: 67% YoYTotal Battery Capex vs TTM Revenue: 208%Proposed QIP Fundraise: ₹600 crCapex Incurred to Date: ₹1,298 crNet Insurance Claim Receivable: ₹186 cr
📅 Short termThe stock is likely to react positively to the strong earnings beat and the clarity provided on the Dahej plant reconstruction and insurance recoveries.
📈 Long termThe company is positioning itself as a critical supplier for Lithium-ion batteries; long-term value depends on the successful ramp-up of the Pakhajan Phase 2 project by March 2027.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (up 64% YoY)
- Debt-to-Equity ratio of 0.86
- Execution risk for large-scale battery chemical projects
Key Highlights
Consolidated Revenue grew 34% YoY to ₹250 crore in Q1 FY27.
PAT increased 67% YoY to ₹17 crore, despite finance costs rising 64% to support expansion.
Board approved a ₹600 crore fundraise via QIP, representing approximately 11% of current market capitalization.
Total Battery Materials project cost estimated at ₹1,795 crore, with ₹1,298 crore (72%) already incurred.
Neogen Ionics revenue reached ₹19 crore in Q1, nearly 50% of its entire FY26 revenue.
👀 What to Watch
Watch for the commencement of commercial production at the rebuilt Dahej plant and the commissioning of the 1,000 MTPA Lithium Electrolyte Salts capacity scheduled for H2 FY27.
₹600 Cr Fundraise Approved via QIP; Subsidiary Borrowing Limit Raised to ₹500 Cr
Neogen Chemicals has received board approval to raise up to ₹600 crore through a Qualified Institutional Placement (QIP) or other modes, representing approximately 11% of its current market capitalization. This capital infusion is significant as it represents nearly 70% of the company's TTM revenue of ₹862 crore, likely intended for its battery chemicals expansion. Additionally, the board set August 13, 2026, as the record date for the final dividend and approved increasing the borrowing limit of its subsidiary, Neogen Morita New Materials, to ₹500 crore. The company is targeting a revenue of ₹1,150 crore by FY28, and this fundraise is a critical step toward that trajectory.
Confidence: HIGH
What changedThe company has moved from planning to formal board approval for a major capital raise and has set the timeline for its annual shareholder proceedings and dividend payouts.
Why it mattersThe fundraise is substantial relative to the company's size (11% of market cap) and is essential for funding the high-growth battery chemicals business. The increased borrowing limit for the subsidiary suggests aggressive expansion plans in specialized materials.
Proposed Fundraise: ₹600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: ₹500 CrDividend Record Date: August 13, 2026TTM Revenue: ₹862 Cr
📅 Short termThe stock may see positive momentum due to the growth-oriented fundraise, though the actual QIP pricing will determine the extent of equity dilution.
📈 Long termThe capital will support Neogen's transition into the EV battery supply chain, which is central to its FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders due to QIP
- Increased leverage risk as subsidiary borrowing limits are raised to ₹500 crore
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved raising up to ₹600 crore via QIP or other permissible securities.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
Record date for final dividend and remote e-voting eligibility set for August 13, 2026.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
Fundraise amount of ₹600 crore is approximately 70% of the TTM revenue of ₹862 crore.
👀 What to Watch
Monitor the announcement of the QIP floor price and the specific utilization plan for the ₹600 crore, particularly regarding the Lithium-ion battery chemicals segment. Investors should also track the progress of the Dahej plant rebuild, which is expected to resume in FY27.
₹600 Cr Fundraise Approved and ₹500 Cr Subsidiary Borrowing Limit Increase
Neogen Chemicals has approved an in-principle fundraise of up to ₹600 crore through QIP or other instruments, representing approximately 11% of its current market capitalization and 70% of its net worth. Additionally, its subsidiary Neogen Morita New Materials is increasing its borrowing limit to ₹500 crore to support expansion. The company has fixed August 13, 2026, as the record date for the final dividend of FY25-26. These moves signal a significant capital push, likely directed toward the company's battery chemicals and electrolyte business.
Confidence: HIGH
What changedThe company has transitioned from planning to formal board approval for a major ₹600 crore capital infusion and significantly expanded the debt capacity of its subsidiary.
Why it mattersThe fundraise is massive relative to the company's current net worth (70%), indicating a high-conviction expansion phase into specialty battery chemicals which is central to their FY28 revenue target of ₹1,150 crore.
Proposed Fundraise: ₹600 croreFundraise vs Net Worth: ~70.3%Subsidiary Borrowing Limit: ₹500 croreDividend Record Date: August 13, 2026TTM Revenue: ₹862 crore
📅 Short termThe stock may see positive momentum due to the growth signal, though the potential for equity dilution from the QIP may cap immediate gains depending on the issue price.
📈 Long termThis is a structural move to capitalize on the EV battery supply chain; successful deployment of ₹1,100 crore in combined new capital/debt could significantly re-rate the company's scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution risk from the ₹600 crore fundraise
- Increased interest burden if subsidiary debt is fully utilized
- Execution risk in the high-tech battery chemicals segment
Key Highlights
Board approved raising up to ₹600 crore via QIP or other eligible securities to fund growth.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
Record date for final dividend and AGM voting eligibility set for August 13, 2026.
CNK & Associates appointed as Internal Auditors for the financial year 2026-27.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
👀 What to Watch
Watch for the specific pricing and timing of the ₹600 crore QIP, as well as management commentary during the AGM regarding the deployment of these funds into the Lithium-ion battery chemical segment.
₹600 Cr Fundraise Approved; Subsidiary Borrowing Limit Increased to ₹500 Cr
Neogen Chemicals has received in-principle board approval to raise up to ₹600 Cr through QIP or other equity instruments, representing approximately 11% of its current market capitalization. Simultaneously, its subsidiary Neogen Morita New Materials is seeking shareholder approval to increase borrowing limits to ₹500 Cr, indicating a major capital push for its battery chemicals business. The company also finalized its Q1 FY27 results and set August 13, 2026, as the record date for the FY26 final dividend. These moves align with the company's strategy to reach ₹1,150 Cr revenue by FY28.
Confidence: HIGH
What changedThe company has transitioned from strategic planning to formal board approval for a major capital raise and significantly higher debt capacity for its key subsidiary.
Why it mattersThe ₹600 Cr fundraise is massive relative to the company's current net worth of ₹853 Cr (~70%), providing the necessary liquidity to scale its high-margin battery chemicals and specialty segments.
Proposed Fundraise: ₹600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: ₹500 CrDividend Record Date: August 13, 2026TTM Revenue: ₹862 Cr
📅 Short termThe stock may see volatility as the market digests the potential equity dilution from the ₹600 Cr fundraise, though the growth signal is strong.
📈 Long termThis capital infusion is critical for Neogen to achieve its FY28 revenue target of ₹1,150 Cr and establish itself in the EV battery supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the proposed ₹600 Cr issuance
- Increased consolidated leverage if subsidiary borrowing is fully utilized
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved raising up to ₹600 Cr via QIP or other eligible securities to fund growth initiatives.
Subsidiary Neogen Morita New Materials to increase borrowing powers under Section 180(1)(c) to ₹500 Cr.
Record date for the final dividend of FY 2025-26 fixed as August 13, 2026.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
Appointment of CNK & Associates as Internal Auditor for the financial year 2026-27.
👀 What to Watch
Monitor the pricing and timing of the ₹600 Cr fundraise to assess equity dilution impact. Track the deployment of funds into the Lithium-ion battery chemical segment, which is the primary growth driver.
₹600 Cr Fundraise Approved; Record Date for Dividend Set for Aug 13, 2026
Neogen Chemicals has received board approval to raise up to ₹600 crore through various instruments, including a Qualified Institutional Placement (QIP). This proposed fundraise is significant, representing approximately 70% of the company's current net worth (₹853 Cr) and 11% of its market capitalization. Additionally, the company has fixed August 13, 2026, as the record date for its final dividend. Its subsidiary, Neogen Morita New Materials, is also seeking to increase its borrowing limit to ₹500 crore to support growth initiatives.
Confidence: HIGH
What changedThe company has formally initiated a large-scale capital raising process and established the timeline for its annual dividend payout and shareholder meeting.
Why it mattersThe ₹600 crore raise is a major capital event intended to fund the company's expansion into battery chemicals and lithium salts. The high magnitude relative to net worth suggests an aggressive growth phase but carries dilution risks for existing shareholders.
Proposed Fundraise: ₹600 croreFundraise vs Net Worth: ~70.3%Fundraise vs Market Cap: ~11.0%Subsidiary Borrowing Limit: ₹500 croreDividend Record Date: 13-Aug-2026
📅 Short termThe stock may react to the potential dilution from the ₹600 crore raise, though the dividend record date provides a minor positive anchor for yield-seeking investors.
📈 Long termThe successful deployment of ₹600 crore into the battery chemicals segment is critical for Neogen to achieve its FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
- Equity dilution from the ₹600 crore fundraise
- Increased leverage risk if the subsidiary utilizes the full ₹500 crore borrowing limit
- Execution risk in the capital-intensive battery chemicals segment
Key Highlights
Board approved a fundraise of up to ₹600 crore via equity or other eligible securities.
Record date for the final dividend for FY 2025-26 is fixed as August 13, 2026.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
CNK & Associates appointed as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the specific terms and pricing of the ₹600 crore fundraise, as it will lead to equity dilution. Watch for the Q1 FY27 results (released concurrently) to see if operational cash flows are improving alongside this capital requirement.
₹600 Cr Fundraise Approved and Subsidiary Borrowing Limit Increased to ₹500 Cr
Neogen Chemicals has received board approval to raise up to ₹600 crore through equity or other instruments, representing approximately 11% of its current market cap and 70% of its net worth. Additionally, its subsidiary Neogen Morita New Materials is seeking shareholder approval to increase borrowing limits to ₹500 crore. The company has also fixed August 13, 2026, as the record date for the final dividend of FY 2025-26. These financial moves align with the company's stated strategy to reach ₹1,150 crore revenue by FY28 through battery chemical expansion.
Confidence: HIGH
What changedThe company has transitioned from strategic intent to formal board approval for a ₹600 crore capital raise and significantly higher debt capacity for its subsidiary.
Why it mattersThe fundraise is massive relative to the company's ₹853 crore net worth (70%) and is essential for funding the high-growth battery chemicals business which is key to their FY28 revenue targets.
Fundraise amount: ₹600 CrFundraise vs Net Worth: ~70.3%Subsidiary borrowing limit: ₹500 CrRecord date: August 13, 2026Fundraise vs Market Cap: ~11.0%
📅 Short termThe market may focus on the potential equity dilution from the ₹600 crore issue, but the record date for the dividend provides a near-term anchor for shareholders.
📈 Long termThis capital infusion is a structural necessity for Neogen to scale its electrolyte and lithium salt capacity; successful execution could significantly re-rate the business as it pivots toward the EV supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the ₹600 crore fundraise
- Increased leverage risk if subsidiary borrowing is fully utilized
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved fundraising of up to ₹600 crore via QIP or other permissible modes
Subsidiary Neogen Morita New Materials to increase borrowing powers to ₹500 crore
Record date for final dividend and AGM eligibility set for August 13, 2026
37th Annual General Meeting scheduled for August 21, 2026
Appointment of CNK & Associates as Internal Auditors for the financial year 2026-27
👀 What to Watch
Monitor the pricing and timing of the ₹600 crore fundraise to assess equity dilution levels. Watch for specific capex deployment updates in the upcoming AGM on August 21, 2026, particularly regarding the Lithium-ion battery chemical segment.
Neogen Chemicals approves Rs 600 Cr fundraise and sets Aug 13 as dividend record date
Neogen Chemicals' board has granted in-principle approval to raise up to Rs 600 crore through equity or other instruments, representing approximately 11% of its current market capitalization. The company also finalized August 13, 2026, as the record date for the FY26 final dividend. Additionally, its subsidiary, Neogen Morita New Materials, is seeking to increase its borrowing limit to Rs 500 crore. While Q1 FY27 results were approved, specific financial figures were not detailed in this summary document.
Confidence: HIGH
What changedThe company has initiated a major capital-raising process and formalized its dividend and AGM timelines.
Why it mattersA Rs 600 crore fundraise is significant relative to the company's TTM revenue of Rs 862 crore, signaling aggressive growth plans in the Lithium-ion battery sector or potential debt restructuring.
Proposed Fundraise: Rs 600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: Rs 500 CrDividend Record Date: August 13, 2026AGM Date: August 21, 2026
📅 Short termThe fundraise approval and dividend timeline are likely to support positive sentiment in the coming weeks.
📈 Long termThe capital infusion and increased borrowing capacity for the subsidiary align with the company's FY28 revenue target of Rs 1,150 crore, focusing on high-growth battery chemicals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution risk from the Rs 600 Cr fundraise
- High debt-to-equity ratio of 0.86 prior to fundraise
Key Highlights
Approved fundraise of up to Rs 600 crore via QIP or other permissible modes
Set August 13, 2026, as the record date for final dividend eligibility
Subsidiary Neogen Morita New Materials to increase borrowing powers to Rs 500 crore
37th Annual General Meeting (AGM) scheduled for August 21, 2026
Appointed CNK & Associates as Internal Auditors for FY 2026-27
👀 What to Watch
Investors should monitor the upcoming Q1 FY27 detailed financial statement and the specific deployment plan for the Rs 600 crore fundraise, particularly regarding the battery chemicals expansion.
CRISIL Downgrades Neogen Chemicals to 'A-/Negative' on Project Delays
CRISIL has downgraded the long-term credit rating of Neogen Chemicals from 'A' to 'A-' and its subsidiary, Neogen Ionics, from 'A-' to 'BBB+', both with a Negative outlook. The downgrade is driven by delays in the company's battery chemicals project and the slow receipt of insurance claims related to the Dahej plant fire (₹14.1 Cr). Total bank facilities rated across the group amount to ₹1,830 Cr, which is approximately 2.12x the company's TTM revenue of ₹862 Cr. This rating action reflects heightened execution risks and potential liquidity pressure.
Confidence: HIGH
What changedCRISIL lowered the credit ratings for both Neogen Chemicals and its subsidiary Neogen Ionics, maintaining a Negative outlook.
Why it mattersThe downgrade signals increased execution risk in the company's EV battery chemical pivot and may lead to higher borrowing costs on its ₹736 Cr debt, potentially impacting net margins which are already thin at 3.4% (TTM).
Total Rated Facilities (Group): ₹1,830 CrRated Facilities vs TTM Revenue: 212.3%Pending Insurance Claim: ₹14.1 CrParent Long-Term Rating: CRISIL A-/NegativeSubsidiary Long-Term Rating: CRISIL BBB+/Negative
📅 Short termNegative sentiment is expected as the market reacts to the formal acknowledgment of project delays and the potential for increased financing costs.
📈 Long termThe structural shift toward battery chemicals is facing teething issues; long-term recovery depends on the timely commissioning of the Dahej SEZ plant and stabilization of the lithium-ion supply chain.
⚠ Risk flags
- Project execution delays
- Liquidity strain from delayed insurance claims
- High debt relative to current revenue
- Negative rating outlook
Key Highlights
Long-term rating for Neogen Chemicals downgraded from CRISIL A/Negative to CRISIL A-/Negative.
Subsidiary Neogen Ionics downgraded from CRISIL A-/Negative to CRISIL BBB+/Negative.
Total bank facilities rated across the group stand at ₹1,830 Cr (₹680 Cr parent, ₹1,150 Cr subsidiary).
Downgrade attributed to delays in the battery chemicals project and pending insurance claims of ₹14.1 Cr.
Short-term rating for the parent company revised from CRISIL A1 to CRISIL A2+.
👀 What to Watch
Investors should monitor the revised commissioning timeline for the battery chemicals project and the Dahej plant rebuild, currently slated for FY27. Watch for potential increases in interest expenses in upcoming quarterly results due to the higher risk premium associated with the downgrade.
CRISIL Downgrades Neogen Chemicals to 'A-/Negative' on Project Delays
CRISIL has downgraded Neogen Chemicals' long-term rating from 'A' to 'A-' and its subsidiary Neogen Ionics from 'A-' to 'BBB+', maintaining a 'Negative' outlook. The downgrade impacts a total of ₹1,830 crore in bank facilities and ₹200 crore in NCDs. The rating action is driven by delays in the company's critical battery chemicals project and a lag in receiving insurance claims related to the Dahej plant fire. This reflects increased execution risk for a company currently trading at a high P/E of 199.8.
Confidence: HIGH
What changedCRISIL lowered the credit ratings for both the parent company and its wholly-owned subsidiary, Neogen Ionics, while maintaining a Negative outlook.
Why it mattersA credit downgrade typically leads to higher interest expenses and signals to the market that the company's aggressive expansion into EV battery chemicals is facing execution and liquidity hurdles.
Total Rated Bank Facilities: ₹1,830 CrRated NCDs: ₹200 CrRated Debt vs TTM Revenue: 235.5%Insurance Claim (Exceptional Item): ₹14.1 CrCurrent Debt-to-Equity: 0.86
📅 Short termThe downgrade is likely to put downward pressure on the stock price in the near term, especially given the high valuation and the 'Negative' outlook from the rating agency.
📈 Long termThe structural growth story depends on the successful ramp-up of the Lithium-ion battery segment; persistent delays could jeopardize the FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
- Project execution delays
- Liquidity strain from delayed insurance claims
- High valuation (P/E 199.8) relative to earnings growth
- Increased cost of debt
Key Highlights
Long-term rating for Neogen Chemicals downgraded to CRISIL A-/Negative from CRISIL A/Negative.
Subsidiary Neogen Ionics Limited rating downgraded to CRISIL BBB+/Negative for ₹1,150 crore in facilities.
Total bank facilities and NCDs under review amount to ₹2,030 crore, which is ~235% of TTM revenue.
Downgrade rationale cites delays in the battery chemicals project and the ₹14.1 crore insurance claim settlement.
Short-term rating for the parent company also downgraded from CRISIL A1 to CRISIL A2+.
👀 What to Watch
Investors should monitor the execution timeline for the battery chemicals project and the Dahej plant rebuild, currently planned for FY27. Watch for the impact of higher borrowing costs on net margins, which are already thin at 3.4% (TTM).
₹155 Cr Total Insurance Received; Neogen Updates on Dahej Fire Recovery and H1FY27 Rebuild
Neogen Chemicals has received an additional ₹15 crore as a fourth on-account insurance payment for the March 2025 Dahej fire, bringing total receipts to ₹155 crore. The company has recognized a total consolidated loss of ₹362.90 crore, representing approximately 42% of its TTM revenue, though it expects to recover ₹348.82 crore through insurance. Production at the affected MPP3 facility remains suspended, with a replacement plant currently under construction and scheduled for commissioning in H1FY27. To mitigate business disruption, the company has shifted critical production to other sites and is leveraging its Patancheru plant expansion.
Confidence: HIGH
What changedThe company received a fresh ₹15 crore tranche of insurance money and provided a concrete H1FY27 timeline for the restoration of its Dahej facility.
Why it mattersThe Dahej fire was a major disruption affecting assets worth 42% of annual revenue; successful insurance recovery and plant rebuilding are critical for the company to reach its FY28 revenue target of ₹1,150 crore.
Total Consolidated Loss: ₹362.90 CrTotal Insurance Received to Date: ₹155 CrLoss vs TTM Revenue: 42.1%Pending Insurance Receivable: ₹193.82 CrRebuild Commissioning Date: H1FY27
📅 Short termThe receipt of ₹15 crore provides minor liquidity support, but the stock's high P/E suggests the market has already factored in a successful recovery.
📈 Long termThe structural recovery depends on the H1FY27 commissioning of the new plant; until then, the company relies on interim production shifts and other sites to maintain volumes.
⚠ Risk flags
- Execution risk in the rapid construction of the replacement plant
- Potential shortfall in final insurance settlement vs recognized receivables
- Prolonged business interruption affecting customer relationships
Key Highlights
Received ₹15 crore as the fourth on-account insurance payment on July 16, 2026.
Total insurance claim received to date stands at ₹155 crore against a recognized receivable of ₹348.82 crore.
Total consolidated loss recognized due to the fire is ₹362.90 crore, including property, plant, and inventory.
Replacement plant at Dahej is scheduled for commissioning in H1FY27 to restore lost capacity.
Net financial impact recognized in FY25 was limited to ₹14.08 crore after accounting for expected insurance recovery.
👀 What to Watch
Monitor the H1FY27 commissioning timeline for the Dahej replacement plant and the final settlement of the remaining ₹193.82 crore insurance receivable to ensure cash flow stability.
₹155 Cr total insurance received; Neogen gets ₹15 Cr fourth on-account payment for Dahej fire
Neogen Chemicals has received an additional ₹15 Crore as the fourth on-account insurance payment related to the March 2025 Dahej fire incident. This brings the total recovery to date to ₹155 Crore, against a total recognized consolidated loss of ₹362.90 Crore. The company has already recognized an insurance receivable of ₹348.82 Crore, implying a net financial impact of ₹14.08 Crore accounted for in FY25. While the affected MPP3 facility remains suspended, a replacement plant is on track for commissioning in H1FY27.
Confidence: HIGH
What changedThe company received a further ₹15 Crore cash inflow from insurers and provided an update on the reconstruction progress of its Dahej facility.
Why it mattersThe insurance receivable of ₹348.82 Crore is significant, representing ~40% of TTM revenue; timely recovery and plant reconstruction are vital for meeting the FY28 revenue target of ₹1,150 Crore.
Fourth on-account payment: ₹15 CroreTotal claim received to date: ₹155 CroreInsurance receivable vs TTM Revenue: 40.46%Total claim received vs Net Worth: 18.17%Consolidated loss recognized: ₹362.90 Crore
📅 Short termPositive impact on liquidity as the company receives cash to fund ongoing reconstruction and operations.
📈 Long termThe rebuilding of the MPP3 facility is a structural necessity to restore full production capacity and achieve long-term growth targets in specialty chemicals.
⚠ Risk flags
- Execution risk in plant reconstruction timeline
- Potential for final insurance settlement to differ from recognized receivables
- Business interruption loss not yet fully quantified or accounted for
Key Highlights
₹15 Crore received as the fourth on-account payment on July 16, 2026
₹155 Crore total on-account insurance claim received to date
₹362.90 Crore total consolidated loss recognized due to the fire incident
H1FY27 scheduled for the commissioning of the replacement plant at Dahej SEZ
₹348.82 Crore total consolidated insurance claim receivable recognized by the company
👀 What to Watch
Monitor the execution timeline for the replacement plant commissioning in H1FY27 and the realization of the remaining ₹193.82 Crore insurance receivable.
Neogen Chemicals Q4 FY26 Revenue Up 22% to ₹247 Cr; FY27 Revenue Guidance ₹875-950 Cr
Neogen Chemicals reported a strong Q4 FY26 with revenue growing 22% YoY to ₹247 crore and EBITDA margins holding steady at 17.8%. The company is aggressively expanding into battery materials, with the Pakhajan Phase 2 project cost revised to ₹1,367 crore for completion by March 2027. Management has provided a standalone revenue guidance of ₹875-950 crore for FY27, driven by the commissioning of new facilities. Despite high debt levels of ₹1,330 crore due to capex, the company maintains a positive outlook on the lithium-ion battery ecosystem.
Key Highlights
Q4 FY26 revenue rose 22% YoY to ₹247 crore, while full-year FY26 revenue reached ₹862 crore.
Inorganic Chemicals segment saw a massive 145% YoY expansion in Q4, contributing ₹53 crore.
Pakhajan Phase 2 capex revised to ₹1,367 crore with a target completion of March 2027.
Management expects standalone revenue of ₹875-950 crore in FY27 following plant commissionings.
Total debt increased to ₹1,330 crore to fund the Dahej rebuild and Neogen Ionics expansion.
👀 What to Watch
Investors should monitor the timely commissioning of the Pakhajan and Dahej facilities in FY27, as these are critical for achieving revenue targets. The high debt levels warrant caution, but the strategic shift toward battery materials offers significant long-term growth potential.
Neogen Chemicals Q4 Revenue Up 22% to INR 247 Cr; INR 161 Cr Promoter Infusion & INR 1 Dividend
Neogen Chemicals reported a robust 22% YoY revenue growth in Q4 FY26, reaching INR 247 crore, driven by high plant utilization and volume growth. While PAT surged 373% to INR 11 crore, this was primarily due to a low base from the previous year's fire incident. A significant highlight is the promoter infusion of INR 161 crore at a 17% premium to the SEBI floor price, signaling strong confidence in the company's pivot toward battery materials. Management has provided a standalone revenue guidance of INR 875–950 crore for FY27 as the rebuilt Dahej plant and Pakhajan facility come online.
Key Highlights
Q4 FY26 consolidated revenue grew 22% YoY to INR 247 crore with EBITDA margins sustaining at 17.8%.
Promoter group to infuse INR 161 crore via preferential allotment at INR 1,610 per share, a 17% premium to floor price.
Management guided for FY27 standalone revenue of INR 875–950 crore, aided by the June 2026 commissioning of the Dahej replacement plant.
Battery materials project (Neogen Ionics) total cost revised to INR 1,795 crore with Pakhajan facility commercialization expected in H2 FY27.
Board recommended a final dividend of INR 1 per equity share for the financial year 2025-26.
👀 What to Watch
Investors should view the promoter infusion at a premium as a strong bullish signal for the company's long-term transition into the EV battery supply chain. Key monitorables include the timely commissioning of the Pakhajan Greenfield project and the successful ramp-up of electrolyte sales in FY27.
Neogen Chemicals Q4 FY26 PAT Jumps 373% to ₹11.4 Cr; Promoters to Infuse ₹161 Cr
Neogen Chemicals reported a strong Q4 FY26 with consolidated revenue growing 22% YoY to ₹246.6 crore, supported by high plant utilization. While PAT surged 373% to ₹11.4 crore due to a low base from the previous year's fire incident, the company is aggressively pivoting toward battery chemicals. The Board approved a ₹161 crore capital infusion from promoters at ₹1,610 per share, representing a 17% premium. Management has provided a standalone revenue guidance of ₹875–950 crore for FY27 as major expansion projects at Dahej and Pakhajan near commissioning.
Key Highlights
Consolidated Q4 FY26 Revenue rose 22% YoY to ₹246.6 crore with EBITDA margins at 17.8%.
Promoter group to infuse ₹161 crore via preferential allotment at a 17% premium to the SEBI floor price.
Battery chemicals project cost revised to ₹1,795 crore; Pakhajan Electrolyte plant on track for H1 FY27 commissioning.
Consolidated Net Debt increased significantly to ₹1,295 crore to fund massive CAPEX in Neogen Ionics.
Board recommended a final dividend of ₹1 per equity share for the financial year ended March 31, 2026.
👀 What to Watch
Investors should take confidence from the promoter's capital infusion at a premium, which validates the long-term growth strategy in battery materials. However, closely monitor the debt-to-equity levels and the timely commissioning of the Pakhajan facility in H1 FY27.
Neogen Chemicals Recommends Re. 1 Dividend; Revises NIL Project Cost to Rs. 1,795 Crore
Neogen Chemicals has approved its FY26 audited results and recommended a final dividend of Re. 1 per share. The company announced a significant revision in the project timelines and costs for its subsidiary, Neogen Ionics Limited (NIL), with total costs now projected at Rs. 1,795 crore. These projects in Dahej and Pakhajan are now expected to be completed by February and March 2027, respectively, due to a shift to Japanese technology and increased localization. Additionally, the company has recovered Rs. 140 crore of its insurance claim from a 2025 fire incident, with Rs. 188.96 crore still outstanding.
Key Highlights
Recommended a final dividend of Re. 1 per equity share for the financial year 2025-26.
Revised total project cost for Neogen Ionics Limited (NIL) to Rs. 1,795 crore (Dahej: Rs. 428 Cr, Pakhajan: Rs. 1,367 Cr).
Project timelines for NIL extended to Feb/Mar 2027 due to design optimization and adoption of Japanese technology.
Outstanding insurance claim receivable stands at Rs. 188.96 crore as of March 31, 2026.
Funding for additional capex to be met through promoter equity infusion and planned JV partner contributions.
👀 What to Watch
Investors should monitor the execution of the Neogen Ionics project as the timeline has shifted to 2027 with increased costs. The successful recovery of the remaining Rs. 188.96 crore insurance claim remains a critical factor for the company's cash flow.
Neogen Chemicals Recommends ₹1 Dividend; Updates ₹1,795 Cr Project Timelines
Neogen Chemicals has recommended a final dividend of ₹1 per equity share for FY 2025-26. The company reported a significant update for its subsidiary, Neogen Ionics, revising the total project cost for Dahej and Pakhajan to ₹1,795 crore with completion timelines now set for early 2027. The Dahej Phase 1 project was delayed to February 2027 due to a shift to Japanese technology and design optimizations. Additionally, the company is still awaiting ₹188.96 crore in insurance claims following a major fire incident in March 2025.
Key Highlights
Recommended a final dividend of ₹1 per equity share for the financial year ended March 31, 2026.
Revised total project cost for Neogen Ionics Limited (NIL) to ₹1,795 crore (₹428 Cr for Dahej and ₹1,367 Cr for Pakhajan).
Dahej Phase 1 timeline extended to February 2027 due to technology changeover and higher localization efforts.
Outstanding insurance claim receivable stands at ₹188.96 crore after receiving ₹140 crore on-account payment.
Auditors issued an unmodified opinion on the audited standalone and consolidated financial results for FY26.
👀 What to Watch
Investors should focus on the execution of the Neogen Ionics expansion as the shift to Japanese technology and revised timelines may delay revenue realization. Monitor the recovery of the remaining insurance claim as it will impact cash flows and liquidity.
